HUTCHMED (China) Limited HCM
Set alert
At close · Oct 30
After hours · Oct 30, 4:02 PM ET
- YTD
- -1.35%
- 1 year
- -8.87%
- Open
- 13.26
- Prev close
- 13.59
- Mkt cap
- 2.29B
- Vol
- 33.49K
- Avg vol
- 66.84K
- EPS
- 0.10
- P/E
- 131.50
- Div yield
- 0.00%
More statistics
- Low
- 13.14
- High
- 13.42
- Forward P/E
- 50.73
- Beta
- 0.36
- Short ratio
- 4.66
- Inst. own
- 2.60%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 4, 2027
- 50-d avg
- 13.64
- 200-d avg
- 13.23
- 1y target
- 20.59
2Y chart
Events in this range
- Jul 2, 2025Earnings: 1.35; estimate -0.31695; surprise 525.93%
- Jul 22, 2025Rating: B of A Securities · Buy → Buy
- Aug 7, 2025Earnings: 2.6; estimate 1.46; surprise 78.08%
- Sep 22, 2025Downgrade: Morgan Stanley · Equal-Weight → Underweight
- Mar 5, 2026Earnings: 0.0005; estimate 2.5; surprise -99.98%
- Mar 10, 2026Rating: B of A Securities · Buy → Buy
- Jul 2, 2026Earnings: 0.046; estimate -0.35806; surprise 112.85%
- Jul 7, 2026Rating: B of A Securities · Buy → Buy
- Jul 23, 2026Rating: Goldman Sachs · Neutral → Neutral
- Jul 30, 2026Earnings: 0.046; estimate 0.145; surprise -68.28%
Signals (97)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 1 day ago |
| SMA: Bearish | Oct 28, 2026 | 3 days ago |
| MACD: Sell Signal | Oct 2, 2026 | 4 weeks ago |
| MACD: Buy Signal | Sep 30, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bullish | Sep 3, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 3, 2026 | 1 month ago |
| RSI: Overbought | Sep 3, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 2 months ago |
| SMA: Bullish | Jul 31, 2026 | 3 months ago |
| SMA: Bearish | Jul 30, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 30, 2026 | 3 months ago |
| SMA: Bullish | Jul 28, 2026 | 3 months ago |
| SMA: Bearish | Jul 17, 2026 | 3 months ago |
| SMA: Bullish | Jul 15, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 24, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 22, 2026 | 4 months ago |
| RSI: Oversold | Jun 16, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| RSI: Oversold | May 12, 2026 | 5 months ago |
| SMA: Bearish | Apr 22, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 22, 2026 | 6 months ago |
| SMA: Bearish | Apr 21, 2026 | 6 months ago |
| SMA: Bullish | Apr 15, 2026 | 6 months ago |
| SMA: Bearish | Apr 14, 2026 | 6 months ago |
| SMA: Bearish | Apr 8, 2026 | 6 months ago |
| SMA: Bullish | Apr 2, 2026 | 7 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Feb 27, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 26, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 25, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 24, 2026 | 8 months ago |
| SMA: Bearish | Feb 23, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 23, 2026 | 8 months ago |
| SMA: Bullish | Feb 20, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 29, 2026 | 9 months ago |
| SMA: Bearish | Jan 27, 2026 | 9 months ago |
| RSI: Overbought | Jan 16, 2026 | 9 months ago |
| SMA: Bullish | Jan 14, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| MACD: Buy Signal | Dec 23, 2025 | 10 months ago |
| RSI: Oversold | Dec 11, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 8, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 5, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 18, 2025 | 11 months ago |
| SMA: Bearish | Nov 7, 2025 | 11 months ago |
| SMA: Bullish | Nov 4, 2025 | 12 months ago |
| MACD: Buy Signal | Nov 3, 2025 | 12 months ago |
| SMA: Bearish | Oct 17, 2025 | 1 year ago |
| SMA: Bullish | Oct 15, 2025 | 1 year ago |
| SMA: Bearish | Oct 14, 2025 | 1 year ago |
| SMA: Bullish | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Oct 10, 2025 | 1 year ago |
| SMA: Bearish | Oct 9, 2025 | 1 year ago |
| SMA: Bullish | Oct 8, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 24, 2025 | 1 year ago |
| SMA: Bearish | Sep 23, 2025 | 1 year ago |
| SMA: Bullish | Sep 12, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 8, 2025 | 1 year ago |
| SMA: Bullish | Sep 5, 2025 | 1 year ago |
| SMA: Bearish | Aug 27, 2025 | 1 year ago |
| SMA: Bearish | Aug 8, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 1, 2025 | 1 year ago |
| RSI: Overbought | Jul 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 10, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 20, 2025 | 1 year ago |
| RSI: Overbought | Jun 10, 2025 | 1 year ago |
| SMA: Bullish | Jun 3, 2025 | 1 year ago |
| MACD: Buy Signal | May 29, 2025 | 1 year ago |
| MACD: Sell Signal | May 9, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| SMA: Bullish | May 5, 2025 | 1 year ago |
| SMA: Bearish | Apr 30, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| SMA: Bearish | Apr 25, 2025 | 1 year ago |
| SMA: Bullish | Apr 22, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 21, 2025 | 1 year ago |
| SMA: Bearish | Apr 15, 2025 | 1 year ago |
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| SMA: Bearish | Apr 4, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 3, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 2, 2025 | 1 year ago |
| SMA: Bullish | Mar 27, 2025 | 1 year ago |
| SMA: Bearish | Mar 25, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 11, 2025 | 1 year ago |
| SMA: Bullish | Feb 19, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 30, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 16, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 2, 2025 | 1 year ago |
| RSI: Oversold | Dec 20, 2024 | 1 year ago |
| RSI: Oversold | Dec 18, 2024 | 1 year ago |
Key statistics
- Market cap
- 2.29B
- Enterprise value
- 1.09B
- Trailing P/E
- 131.50
- Forward P/E
- 50.73
- PEG ratio
- 0.00
- Price / sales
- 4.16
- Price / book
- 1.81
- EPS (TTM)
- 0.10
- Beta
- 0.36
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 3.26%
- Revenue (TTM)
- 549.12M
- Revenue growth
- 0.20%
- Free cash flow
- -18.88M
- Total cash
- 1.38B
- Total debt
- 94.51M
- Return on equity
- 1.46%
- Shares outstanding
- 173.81M
- Short % of float
- 0.25%
- 50-day average
- 13.64
- 200-day average
- 13.23
Analyst view
Consensus: strong buy
- Target (low)
- 13.60
- Target (mean)
- 20.59
- Target (high)
- 33.27
- Strong buy1
- Buy9
- Hold2
- Sell0
- Strong sell0
Next earnings
Mar 4, 2027
Expected Mar 4, 2027. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 4, 2027 | Dec 30, 2026 | 0.21 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 0.145 | 0.046 | -0.10 | -68.28% |
| Jul 2, 2026 | Mar 31, 2026 | -0.35806 | 0.046 | +0.40 | +112.85% |
| Mar 5, 2026 | Dec 31, 2025 | 2.50 | 0.0005 | -2.50 | -99.98% |
| Aug 7, 2025 | Jun 30, 2025 | 1.46 | 2.60 | +1.14 | +78.08% |
| Jul 2, 2025 | Mar 31, 2025 | -0.31695 | 1.35 | +1.67 | +525.93% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 23, 2026 | Goldman Sachs | main | Neutral | Neutral |
| Jul 7, 2026 | B of A Securities | main | Buy | Buy |
| Mar 10, 2026 | B of A Securities | main | Buy | Buy |
| Sep 22, 2025 | Morgan Stanley | down | Equal-Weight | Underweight |
| Jul 22, 2025 | B of A Securities | main | Buy | Buy |
| Aug 1, 2024 | Goldman Sachs | main | Neutral | Neutral |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Hong Kong
- Website
- hutch-med.com
News
- Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
- Reported Earlier, HUTCHMED Says FDA Grants Orphan Drug Designation To Sovleplenib For Primary Immune Thrombocytopenia, Making It Eligible For 7 Years Of US Market Exclusivity
- HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
- Firms in Asia Pacific Embrace Unified Workday Platforms
- Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
- AI Brings U.S. Enterprises More Value from Workday
- HUTCHMED Highlights SANOVO Phase III Data At ESMO, ORPATHYS Plus TAGRISSO Cuts Progression Or Death Risk 44% In First-Line EGFR-Mutated Lung Cancer, Improves OS; China Supplemental NDA Planned
- HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
- HUTCHMED Announced At ESMO Sunday, SAFFRON Phase III Shows ORPATHYS Plus TAGRISSO Cut Progression Or Death Risk 45%, Death Risk 32% Versus Chemotherapy In MET-Driven EGFR-Mutated Lung Cancer
- HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
Your note
Sign in to keep a note on HCM — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Schroder Investment Management Group | 0.85% | 1,477,494 | 19.43M | Jun 29, 2026 |
| Allianz Asset Management GmbH | 0.39% | 674,511 | 8.87M | Jun 29, 2026 |
| State Street Corporation | 0.18% | 313,611 | 4.12M | Jun 29, 2026 |
| Aia Group Ltd | 0.17% | 291,229 | 3.83M | Jun 29, 2026 |
| M&G Plc | 0.14% | 242,791 | 3.19M | Jun 29, 2026 |
| Amundi | 0.12% | 204,385 | 2.69M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Steward Funds Inc-Steward Values Enhanced International Fund | 0.05% | 84,097 | 1.11M | Jul 30, 2026 |
| Tema ETF Trust-Tema Oncology ETF | 0.04% | 67,823 | 891.87K | May 30, 2026 |
| SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Developed World ex-US E | 0.04% | 71,242 | 936.83K | Sep 29, 2026 |
| SPDR-EUROPE-SSgA SPDR ETFS Europe I-State Street SPDR MSCI Emerging Ma | 0.03% | 44,991 | 591.63K | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.01% | 16,399 | 215.65K | Aug 30, 2026 |
| Dimensional ETF Trust-Dimensional World ex U.S. Core Equity 2 ETF | 0.00% | 2,110 | 27.75K | Jul 30, 2026 |